Ottobock (OBCK) Q3 2025 earnings summary

Executive summary

• Core revenue grew 13.6% year-to-date (11.5% organic), driven by robust sales, five key product launches, and multiple acquisitions, with underlying core EBITDA margin expanding by three percentage points to 24.3%.

• Free cash flow increased by 55% to €172.8 million, reflecting higher operating cash flow and improved working capital.

• Adjusted net income rose to €118.7 million, mainly due to higher EBITDA and margin improvement.

• Strategic initiatives included new product launches in prosthetics, neuro-orthotics, and exoskeletons, as well as investments in ONWARD Medical and divestments of non-core businesses.

• Successful IPO in October 2025 raised €100.0 million, strengthening the balance sheet and market position.

Financial highlights

• Core revenue reached €1,157.7 million, up 13.6% year-over-year, with underlying core EBITDA at €281.1 million and margin at 24.3%.

• Gross profit increased to €645.4 million, with gross margin improving to 53.0% from 50.2%.

• Adjusted net income margin improved to 9.7% from 5.6%, with earnings per share at €0.87.

• Net leverage improved to 2.8x, with net debt at €1,081.9 million as of September 30, 2025.

• Free cash flow margin increased, reflecting higher profitability and cash generation.

Outlook and guidance

• Guidance for 2025 narrowed to the upper half of previous ranges: core revenue growth expected at 11.5%-13%, organic growth at 10.5%-12%.

• Underlying core EBITDA margin confirmed at 25%-26%.

• Management remains conservative in guidance, aiming to under-promise and over-deliver.

• For 2026, continued expansion from new products and reimbursement opportunities is expected, though growth may moderate after a strong 2025.